Keine Notizen für die Folie
Survival of patients receiving fludarabine (F), fludarabine and cyclophosphamide or mitoxantrone (FC/M), and FCR as initial therapy of CLL at the M. D. Anderson Cancer Center. Six-year overall survivals were 54%, 59%, and 77%, respectively.
Fig 1. Outcome after allogeneic hematopoietic stem-cell transplantation (HCT) in patients with 17p–chronic lymphocytic leukemia (CLL). (A) The probabilities of overall and progression-free survival in 44 patients with 17p–CLL at 3 years after allogeneic HCT were 44% (95% CI, 28% to 60%) and 37% (95% CI, 22% to 52%), respectively. (B) The cumulative incidences of relapse and nonrelapse mortality at 3 years were 30% (95% CI, 16% to 44%) and 32% (95% CI, 18% to 46%), respectively.